Latest Regenerative February 25, 2026 News

Johnson & Johnson Invests $1 Billion in Next-Gen Cell Therapy Manufacturing in Pennsylvania

This is part of J&J's $55B investment in US manufacturing over the next few years.

Cancer, Manufacturing

February 25, 2026

Innovacell Seeks $92M in Tokyo IPO to Advance Stem Cell Therapy Development

The company is developing autologous cell therapies for fecal and urinary incontinence tied to weakened sphincter muscles.

Business, Manufacturing

February 25, 2026

Keck Medicine of USC Starting Parkinson’s Stem Cell Therapy Trial

Keck Medicine of USC is participating in a small Phase 1 clinical trial evaluating the safety and early effectiveness of implanting induced pluripotent stem cell-derived dopamine-producing cells into the brain for Parkinson’s disease.

iPSC, Neurology

February 25, 2026

ENCell Receives FDA Orphan Drug for DMD Stem Cell Therapy

ENCell's umbilical cord-derived mesenchymal stem cell therapy candidate EN001 received FDA orphan drug designation for Duchenne muscular dystrophy, marking its second designation after Charcot-Marie-Tooth disease and positioning it as a potential platform therapy for rare neuromuscular diseases.